Beauty From Within Becomes a Boardroom Priority

For years, “beauty from within” occupied a relatively small corner of the beauty and wellness market: collagen powders, biotin capsules and hair-and-nails gummies positioned alongside traditional skincare.

In 2026, the category became a boardroom priority.

The clearest signal came in August, when Procter & Gamble agreed to acquire Thorne for $3.8 billion. Thorne brings more than a portfolio of supplements: scientific credibility, practitioner relationships, vertically integrated manufacturing, and a position in personalised health. The transaction, which remains subject to customary approvals, demonstrates how highly strategic buyers now value trusted, science-led wellness platforms. (P&G announcement)

But P&G is not acting alone.

Unilever Ventures has taken a minority stake in NOVOS, a science-led longevity company combining supplements with biological-age measurement. Unilever itself acquired 80% of US greens-supplement company Grüns for €767 million. In India, Hindustan Unilever invested ₹824 crore to acquire the remaining 49% of OZiva, a plant-based consumer-wellness brand operating across lifestyle nutrition, women’s health and hair-and-beauty supplements.

Investment is also flowing into more specialised propositions. Mubadala invested $36.5 million in L-Nutra, bringing the company’s Series D proceeds to $83.5 million and supporting its vision of clinically validated nutrition for longevity. Create Wellness, known for its creatine gummies, raised $20 million from investors including Alliance Consumer Growth, Impact Capital and Unilever Ventures. European private-equity firm Ardian acquired a minority stake in Spain’s science-backed supplement company IVB Wellness Lab.

Meanwhile, Metagenics acquired the practitioner-recommended probiotic company Symprove; STADA purchased 16 vitamin, mineral and supplement brands from Orifarm; and private capital continued assembling consumer-health and supplement platforms across Europe.

These are not isolated transactions. They point to a structural shift in how major consumer companies and investors understand the future of beauty, wellness and preventative health.

They are not simply buying capsules and powders. They are buying credibility, consumer trust, repeat-purchase relationships, practitioner access, proprietary data, scientific capabilities and a route into the rapidly expanding longevity economy.

Beauty, nutrition and longevity are becoming one ecosystem

The traditional distinction between beauty products and health products is becoming increasingly difficult to maintain.

Consumers already understand that the appearance and function of their skin are influenced by sleep, stress, hormonal changes, metabolic health, inflammation, nutrition and the gut microbiome. A topical product may support the skin barrier or address visible signs of ageing, but it cannot independently resolve all the systemic factors affecting skin health.

This does not make skincare less relevant. It changes the role it plays.

The emerging model connects topical skincare with ingestible nutrition, diagnostics, professional guidance and behavioural support. Serums are paired with capsules. Clinics combine aesthetic treatments with metabolic or hormonal assessment. Supplement recommendations are informed by questionnaires, blood tests, microbiome profiles or biological-age measurements. Apps help consumers track adherence, symptoms and changes over time.

The centre of gravity is consequently moving from individual products towards ongoing protocols: personalised combinations of topical, ingestible, clinical and lifestyle interventions designed to produce measurable outcomes over time.

This helps explain why transactions are also occurring around the infrastructure surrounding supplements.

In 2026, Infinite Epigenetics acquired Tally Health, bringing together epigenetic biological-age testing, consumer longevity services and personalised interventions, including supplements. Function Health acquired SuppCo, a platform designed to help consumers evaluate, organise and consistently follow their supplement routines.

The strategic opportunity is no longer limited to selling a supplement. It is to connect three previously fragmented activities:

measuring what is happening in the body, selecting an appropriate intervention and determining whether it is working.

That is a much more valuable relationship than a one-off product sale, but it is also significantly more difficult to build responsibly.

The barrier to entry has fallen; the barrier to credibility has risen

Launching a supplement has never been easier. Contract manufacturers, ready-made formulations, direct-to-consumer infrastructure and creator-led marketing can bring an attractive new brand to market remarkably quickly.

Building sustained relevance, trust and repeat purchase has never been harder.

The shelf is crowded with products using similar ingredients, claims and visual language. Consumers encounter competing advice from brands, practitioners, influencers, podcasts and social-media communities. Longevity terminology is frequently applied to products without a clear definition of what the product is expected to change or how that change would be measured.

As competition intensifies, scientific substantiation is becoming the price of entry rather than an optional differentiator.

For brands, that introduces questions many traditional beauty businesses have not previously had to answer:

• Is there credible evidence for the ingredient, the finished formulation or both?
• Is the dose used in the product consistent with the dose used in the research?
• Is the active stable and bioavailable?
• Can the claimed benefit be objectively measured?
• Is the selected biomarker clinically meaningful, or merely easy to test?
• How long would an intervention need to be used before a change could reasonably be expected?
• Does a short-term change in a biomarker represent a durable improvement in health?
• How do claims and regulatory obligations differ across supplements, foods, cosmetics and medical services?
• Can production, testing and quality systems maintain their standards as the brand scales?

Rapid revenue growth is one achievement. Building the scientific, regulatory and operational infrastructure to support that growth is another.

The brands with the greatest long-term potential will connect formulation science, quality control, evidence, data, practitioner education, consumer experience and distribution. A compelling story may stimulate trial, but trust and demonstrable value will determine retention.

The consumer trust problem

Consumers have never been more interested in their own biology. Wearables, blood testing, continuous glucose monitoring, microbiome services and biological-age assessments have made personal health data more accessible than ever.

But access to more information does not necessarily produce greater understanding.

Consumers face a growing number of products and an equally large number of questions. Which supplement is appropriate for me? Is this a high-quality formulation or simply sophisticated packaging? Can I take these ingredients together? How long should I use them? What result should I expect? How will I know whether they are working?

The language of longevity makes those questions even more consequential. Claims to “slow ageing,” “reverse biological age” or “support cellular rejuvenation” can sound precise while remaining difficult to define or substantiate.

A biological-age score may change without demonstrating that a person’s underlying ageing trajectory has been permanently altered. Different biological clocks may measure different aspects of ageing and produce different results. A favourable movement in one biomarker may be encouraging, but it is not automatically equivalent to better function, reduced disease risk or longer healthspan.

This is the central paradox of the market: supplements and longevity have never attracted more investment, innovation or consumer demand, yet the category has rarely been more confusing.

Every exaggerated claim weakens confidence in the serious science developing alongside it.

Where the market opportunities are

The next phase of growth will not come simply from adding another general-purpose supplement to an already crowded shelf. The strongest opportunities sit where consumer needs are substantial, scientific differentiation is possible and the existing experience remains fragmented.

Women’s health and life-stage nutrition remain particularly underdeveloped. Consumers need more credible solutions tailored to menstruation, fertility, pregnancy, perimenopause, menopause, metabolic change, bone health, sleep, cognition and healthy ageing. The commercial success of propositions such as OZiva reflects a broader shift away from generic “women’s wellness” towards more specific physiological needs and life stages.

Beauty diagnostics and measurable outcomes offer another opening. Brands and clinics can move beyond before-and-after photography by developing responsible ways to assess skin-barrier function, inflammation, hydration, recovery and resilience. The opportunity is not to present skin as a perfect proxy for whole-body biological age, but to use it as an accessible, dynamic organ through which aspects of ageing biology can be studied and communicated.

Personalised protocols can create more value than standalone products, particularly when recommendations reflect an individual’s goals, health context, behaviours and available diagnostic information. However, personalisation must mean more than a quiz that routes everyone towards a similar subscription. The strongest models will explain why a recommendation was made, how it should be used and what outcome will be monitored.

Practitioner-led distribution is likely to become increasingly important. Longevity clinics, dermatologists, aesthetic doctors, pharmacists, nutrition professionals and wellness practitioners occupy a position of trust at the point where highly engaged consumers make decisions. Brands that earn professional recommendation through evidence, education and reliable quality may build stronger retention than those relying exclusively on paid consumer acquisition.

Adherence and outcome-tracking platforms represent an important but less visible opportunity. Even a well-formulated intervention cannot produce its intended result if consumers do not take it consistently. Tools that help people understand their routines, avoid inappropriate combinations, maintain adherence and evaluate progress could become a valuable layer between diagnostics and products.

Finally, there is significant opportunity in scientific translation. Consumers do not need every technical detail, but they do need clear explanations of what a product can reasonably do, what the evidence supports, how long results may take and where uncertainty remains. In a noisy market, honest communication can become a competitive advantage.

What the investment activity is really telling us

The major deals of 2026 reveal several characteristics investors and strategic acquirers increasingly value:

• Scientific and practitioner credibility, as demonstrated by Thorne and Symprove.
• Convenient daily formats capable of moving specialist ingredients into mainstream routines, as seen with Grüns and Create Wellness.
• Strong positions in women’s health and beauty from within, illustrated by OZiva.
• Clinically supported longevity and nutrition-as-medicine models, represented by L-Nutra.
• Diagnostic and data capabilities that connect recommendations with measurable outcomes, as seen in NOVOS, Tally Health and SuppCo.
• Repeat-purchase models and direct consumer relationships that can extend beyond an individual product.

The emerging investment question is therefore not simply, “Which supplement brand is growing fastest?”

It is:

Which businesses can become trusted, recurring consumer-health platforms built around credible science, measurable outcomes and sustained behaviour change?

Why we are bringing this conversation to INNOCOS Zurich

We built the INNOCOS Zurich agenda around this inflexion point because the convergence of beauty, supplements and longevity raises questions that no single part of the industry can answer alone.

At INNOCOS Zurich, taking place from 9–11 September, Nicole Bensi, Global Vice President of Wellness Insights at Mintel, will explore “Winning the Future of Wellness: The New Rules of Competition.” The session will examine why efficacy is becoming the price of entry, how consumer expectations are changing and why prediction may become the next stage beyond personalisation.

Our panel, “From Products to Protocols: The Next Evolution of Consumer Health,” will consider what it takes to move beyond standalone products and treatments toward personalised systems that support adherence and lasting outcomes. It will bring together the perspectives of brands, clinics and consumer-health businesses to examine who owns the relationship, the data and the responsibility for results.

These principles also underpin the Beauty & Longevity CHOICE Awards. Entries are assessed not only for novelty or presentation, but for the quality of the science supporting their claims. In a category saturated with promises, one of the most useful things an industry platform can do is ask for the evidence.

The supplement wave in beauty is real, and the investment activity of 2026 suggests it is accelerating. But the greatest opportunity is not simply to make the category bigger. It is to make it more credible, more measurable and more useful to the consumer.

That means building on foundations of evidence, quality, honest claims and genuine consumer understanding.

That is the conversation we are bringing to Zurich and we invite you to be part of it.

Join us at INNOCOS Zurich, 9–11 September 2026: www.innocosevents.com/events/zurich-2026